Neo-volumab news.
Building off an earlier pilot trial, the phase 3 CheckMate-816 has announced it confirms the addition of nivolumab to neoadjuvant chemo for resectable non-small cell lung cancer improves pathologic complete response rates. | Bristol Myers Squibb 2020
Comments
Post a Comment